Autologous hematopoietic stem cell transplant (HSCT) provides a long-term survival benefit, when compared with interferon (IFN)-alfa maintenance, in patients with advanced mantle cell lymphoma (MCL), according to research published in The Lancet Haematology.¹ Prior results from this study showed a progression-free survival (PFS) benefit with autologous HSCT, but it wasn’t...
Latest News
THE WOODLANDS, Texas — Autonomix Medical, Inc. a medical device company focused on advancing innovative technologies to revolutionize how diseases involving the nervous system are diagnosed and treated, today announced successful completion of an animal safety study evaluating the Company’s proprietary ablation technology. All safety inputs for the study were...
THE WOODLANDS, TX — Autonomix Medical, Inc. a medical device company focused on advancing innovative technologies to revolutionize how diseases involving the nervous system are diagnosed and treated, today announced that it has received authorization from the Uzbekistan Ethics Committee to open the clinical trial site for its proof-of-concept human...
DUBLIN, Ireland – Avadel Pharmaceuticals plc (Nasdaq: AVDL) today announced that the U.S. Food and Drug Administration (FDA) has accepted for review the Company’s New Drug Application (NDA) for FT218, an investigational, once-nightly formulation of sodium oxybate for the treatment of excessive daytime sleepiness and cataplexy in adults with narcolepsy....
DUBLIN, Ireland – Avadel Pharmaceuticals plc (Nasdaq: AVDL), a company focused on transforming medicines to transform lives, today announced its support of the third annual World Narcolepsy Day on Wednesday, September 22. FT218 is the Company’s current lead drug candidate, an investigational formulation of sodium oxybate designed to be taken once at...
Seattle — Avalyn Pharma Inc., a clinical-stage biopharmaceutical company focused on the development of targeted therapies for life-threatening pulmonary diseases, reported that results from the Phase 1b ATLAS study were published online in Thorax, an official journal of the British Thoracic Society. The study assessed safety and efficacy of AP01...
Seattle — Avalyn Pharma Inc., a clinical-stage biopharmaceutical company focused on development of targeted therapies for life-threatening pulmonary diseases, reported top-line results from the company’s Phase 1 trial for AP02 (inhaled nintedanib). AP02 was generally well tolerated, with no serious adverse events (SAEs) reported among the participants who were administered...
SEATTLE, WA — Avalyn Pharma Inc., a clinical-stage biopharmaceutical company focused on development of targeted inhalation therapies for life-threatening pulmonary diseases, today announced the presentation of preclinical data that supported the completed Phase 1a trial of AP02 (inhaled nintedanib) as well as clinical data for AP01 (inhaled pirfenidone) at the...
WATERTOWN, Mass. — AvenCell Therapeutics, Inc., a leading clinical-stage cell therapy company focused on advancing both autologous and allogeneic switchable CAR-T cell therapies, today announced that it has dosed the first patient in a Phase IA study with AVC-201 for the treatment of relapsed/refractory Acute Myeloid Leukemia (AML) and other selected...
Miami — Avenue Therapeutics, Inc. (Nasdaq: ATXI) (“Avenue” or the “Company”), a specialty pharmaceutical company focused on the development and commercialization of therapies for the treatment of rare and neurologic diseases, announced that it has entered into an exclusive license agreement with AnnJi Pharmaceutical Co., Ltd. (“AnnJi”), a Taiwanese clinical-stage...